Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Patients' usability of seven most used dry-powder inhalers in COPD.

Dal Negro RW, Turco P, Povero M.

Multidiscip Respir Med. 2019 Sep 13;14:30. doi: 10.1186/s40248-019-0192-5. eCollection 2019.

2.

Acute cough in Italian children: parents' beliefs, approach to treatment, and the family impact.

Dal Negro RW, Zanasi A, Turco P, Povero M.

Multidiscip Respir Med. 2019 Apr 4;14:16. doi: 10.1186/s40248-019-0180-9. eCollection 2019.

3.

Cost-effectiveness of the COPD Patient Management European Trial home-based disease management program.

Bourbeau J, Granados D, Roze S, Durand-Zaleski I, Casan P, Köhler D, Tognella S, Viejo JL, Dal Negro RW, Kessler R.

Int J Chron Obstruct Pulmon Dis. 2019 Mar 14;14:645-657. doi: 10.2147/COPD.S173057. eCollection 2019.

4.

COPD: The Annual Cost-Of-Illness during the Last Two Decades in Italy, and Its Mortality Predictivity Power.

Dal Negro RW.

Healthcare (Basel). 2019 Mar 1;7(1). pii: E35. doi: 10.3390/healthcare7010035. Review.

5.

Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.

Dal Negro R, Pozzi E, Cella SG.

Pulm Pharmacol Ther. 2018 Dec;53:80-85. doi: 10.1016/j.pupt.2018.10.005. Epub 2018 Oct 21. Review.

PMID:
30352285
6.

Cost of acute cough in Italian children.

Dal Negro RW, Turco P, Povero M.

Clinicoecon Outcomes Res. 2018 Sep 17;10:529-537. doi: 10.2147/CEOR.S167813. eCollection 2018.

7.

Fluticasone furoate/vilanterol 92/22 µg once a day: a 12-month study on outcomes in mild to moderate asthma.

Dal Negro RW, Bonadiman L, Turco P.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618789894. doi: 10.1177/1753466618789894.

8.
9.

Cost of influenza and influenza-like syndromes (I-LSs) in Italy: Results of a cross-sectional telephone survey on a representative sample of general population.

Dal Negro RW, Turco P, Povero M.

Respir Med. 2018 Aug;141:144-149. doi: 10.1016/j.rmed.2018.07.001. Epub 2018 Jul 4.

PMID:
30053960
10.
11.

Influenza and influenza-like syndromes: the subjects' beliefs, the attitude to prevention and treatment, and the impact in Italian general population.

Dal Negro RW, Zanasi A, Turco P, Povero M.

Multidiscip Respir Med. 2018 Mar 1;13:7. doi: 10.1186/s40248-018-0119-6. eCollection 2018.

12.

COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD.

Kessler R, Casan-Clara P, Koehler D, Tognella S, Viejo JL, Dal Negro RW, Díaz-Lobato S, Reissig K, Rodríguez González-Moro JM, Devouassoux G, Chavaillon JM, Botrus P, Arnal JM, Ancochea J, Bergeron-Lafaurie A, De Abajo C, Randerath WJ, Bastian A, Cornelissen CG, Nilius G, Texereau JB, Bourbeau J.

Eur Respir J. 2018 Jan 11;51(1). pii: 1701612. doi: 10.1183/13993003.01612-2017. Print 2018 Jan.

13.

COPD management as a model for all chronic respiratory conditions: report of the 4th Consensus Conference in Respiratory Medicine.

Nardini S, De Benedetto F, Sanguinetti CM, Bellofiore S, Carlone S, Privitera S, Sagliocca L, Tupputi E; with the collaboration of The Consensus Conference Group, Baccarani C, Caiffa G, Calabrese MC, Capuozzo A, Cauchi S, Conio V, Coratella G, Crismancich F, Dal Negro RW, Dellarole F, Delucchi M, Favaretti C, Forte S, Gallo FM, Giuliano R, Grandi M, Grillo A, Gualano MR, Guffanti E, Locicero S, Lombardo FP, Mantero M, Marasso R, Martino L, Mastroberardino M, Mereu C, Messina R, Neri M, Novelletto BF, Parente P, Pasquinucci S, Pistolesi M, Polverino M, Posca A, Richeldi L, Roccia F, Giustini ES, Salemi M, Santacroce S, Schisano M, Schisano M, Selvi E, Silenzi A, Soverina P, Taranto C, Ugolini M, Visaggi P, Zanasi A.

Multidiscip Respir Med. 2017 Nov 10;12:28. doi: 10.1186/s40248-017-0109-0. eCollection 2017.

14.

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.

Dal Negro RW, Wedzicha JA, Iversen M, Fontana G, Page C, Cicero AF, Pozzi E, Calverley PMA; RESTORE group; RESTORE study.

Eur Respir J. 2017 Oct 12;50(4). pii: 1700711. doi: 10.1183/13993003.00711-2017. Print 2017 Oct.

15.

Patient Related Outcomes-BODE (PRO-BODE): A composite index incorporating health utilization resources predicts mortality and economic cost of COPD in real life.

Dal Negro RW, Celli BR.

Respir Med. 2017 Oct;131:175-178. doi: 10.1016/j.rmed.2017.08.019. Epub 2017 Aug 24.

PMID:
28947025
16.

Instant velocity and consistency of emitted cloud change by the different levels of canister filling with Metered Dose Inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study.

Dal Negro RW, Longo P, Ziani OV, Bonadiman L, Turco P.

Multidiscip Respir Med. 2017 May 29;12:13. doi: 10.1186/s40248-017-0096-1. eCollection 2017.

17.

Survey on attitudes of Italian pediatricians toward cough.

Zanasi A, Morcaldi L, Cazzato S, Mazzolini M, Lecchi M, Morselli-Labate AM, Mastroroberto M, Dal Negro RW.

Clinicoecon Outcomes Res. 2017 Mar 16;9:189-199. doi: 10.2147/CEOR.S129696. eCollection 2017.

18.

Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months.

Riccio AM, Mauri P, De Ferrari L, Rossi R, Di Silvestre D, Benazzi L, Chiappori A, Dal Negro RW, Micheletto C, Canonica GW.

Clin Transl Allergy. 2017 Mar 9;7:6. doi: 10.1186/s13601-017-0143-1. eCollection 2017.

19.

Cost of persistent asthma in Italy.

Dal Negro RW, Distante C, Bonadiman L, Turco P, Iannazzo S.

Multidiscip Respir Med. 2016 Dec 16;11:44. doi: 10.1186/s40248-016-0080-1. eCollection 2016.

20.

Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?

Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Borg S, Dal Negro RW, Hansen RN, Jansson SA, Leidl R, Risebrough N, Samyshkin Y, Wacker ME, Rutten-van Mölken MPMH.

Value Health. 2016 Sep - Oct;19(6):800-810. doi: 10.1016/j.jval.2016.04.002. Epub 2016 May 21.

21.

Cough: impact, beliefs, and expectations from a national survey.

Dal Negro RW, Mazzolini M, Turco P, Zanasi A.

Multidiscip Respir Med. 2016 Sep 27;11:34. eCollection 2016.

22.

Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.

Dal Negro RW, Visconti M.

Pulm Pharmacol Ther. 2016 Dec;41:48-51. doi: 10.1016/j.pupt.2016.09.007. Epub 2016 Sep 17.

PMID:
27651323
23.

Dry-powder inhalers in patients with persistent airflow limitation: usability and preference.

Dal Negro RW, Povero M.

Multidiscip Respir Med. 2016 Sep 5;11(1):31. doi: 10.1186/s40248-016-0068-x. eCollection 2016.

24.

Cultural and linguistic validation of the NHQ-2 Questionnaire: a specific instrument for assessing patient's usability of inhalation devices.

Dal Negro RW, Povero M.

Multidiscip Respir Med. 2016 Aug 23;11(1):32. doi: 10.1186/s40248-016-0067-y. eCollection 2016.

25.

Fluticasone furoate/Vilanterol 92/22 μg once-a-day vs Beclomethasone dipropionate/ Formoterol 100/6 μg b.i.d.: a 12-week cost analysis in mild-to-moderate asthma.

Dal Negro RW, Distante C, Bonadiman L, Turco P, Iannazzo S.

Multidiscip Respir Med. 2016 Jun 6;11:20. doi: 10.1186/s40248-016-0055-2. eCollection 2016.

26.
27.

The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life.

Dal Negro RW, Celli BR.

Multidiscip Respir Med. 2016 Mar 3;11:10. doi: 10.1186/s40248-016-0045-4. eCollection 2016.

28.

Acceptability and preference of three inhalation devices assessed by the Handling Questionnaire in asthma and COPD patients.

Dal Negro RW, Povero M.

Multidiscip Respir Med. 2016 Feb 10;11:7. doi: 10.1186/s40248-016-0044-5. eCollection 2015.

29.

Prevalence of different comorbidities in COPD patients by gender and GOLD stage.

Dal Negro RW, Bonadiman L, Turco P.

Multidiscip Respir Med. 2015 Aug 5;10(1):24. doi: 10.1186/s40248-015-0023-2. eCollection 2015.

30.

Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.

Dal Negro RW, Visconti M, Turco P.

Pulm Pharmacol Ther. 2015 Aug;33:47-51. doi: 10.1016/j.pupt.2015.06.004. Epub 2015 Jun 23.

PMID:
26116425
31.

Cognitive dysfunction in severe chronic obstructive pulmonary disease (COPD) with or without Long-Term Oxygen Therapy (LTOT).

Dal Negro RW, Bonadiman L, Bricolo FP, Tognella S, Turco P.

Multidiscip Respir Med. 2015 Apr 19;10(1):17. doi: 10.1186/s40248-015-0013-4. eCollection 2015.

32.

Cough hypersensitivity syndrome: clinical measurement is the key to progress.

Morice AH, Millqvist E, Belvisi MG, Bieksiene K, Birring SS, Chung KF, Dal Negro RW, Dicpinigaitis P, Kantar A, McGarvey LP, Pacheco A, Sakalauskas R, Smith JA.

Eur Respir J. 2015 May;45(5):1509-10. doi: 10.1183/09031936.00014215. No abstract available.

33.

Dry powder inhalers and the right things to remember: a concept review.

Dal Negro RW.

Multidiscip Respir Med. 2015 Apr 3;10(1):13. doi: 10.1186/s40248-015-0012-5. eCollection 2015.

34.

Costs of illness analysis in Italian patients with chronic obstructive pulmonary disease (COPD): an update.

Dal Negro RW, Bonadiman L, Turco P, Tognella S, Iannazzo S.

Clinicoecon Outcomes Res. 2015 Mar 16;7:153-9. doi: 10.2147/CEOR.S77504. eCollection 2015.

35.

Current Annual Cost Calculation is the Best Predictor of Mortality at Three Years in COPD.

Dal Negro RW.

Value Health. 2014 Nov;17(7):A590-1. doi: 10.1016/j.jval.2014.08.2024. Epub 2014 Oct 26. No abstract available.

36.

Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients.

Mauri P, Riccio AM, Rossi R, Di Silvestre D, Benazzi L, De Ferrari L, Dal Negro RW, Holgate ST, Canonica GW.

Immunol Lett. 2014 Nov;162(1 Pt A):2-10. doi: 10.1016/j.imlet.2014.08.010. Epub 2014 Sep 3.

37.

Expert opinion on the cough hypersensitivity syndrome in respiratory medicine.

Morice AH, Millqvist E, Belvisi MG, Bieksiene K, Birring SS, Chung KF, Dal Negro RW, Dicpinigaitis P, Kantar A, McGarvey LP, Pacheco A, Sakalauskas R, Smith JA.

Eur Respir J. 2014 Nov;44(5):1132-48. doi: 10.1183/09031936.00218613. Epub 2014 Aug 19.

38.

Extent and prevalence of cognitive dysfunction in chronic obstructive pulmonary disease, chronic non-obstructive bronchitis, and in asymptomatic smokers, compared to normal reference values.

Dal Negro RW, Bonadiman L, Tognella S, Bricolo FP, Turco P.

Int J Chron Obstruct Pulmon Dis. 2014 Jun 26;9:675-83. doi: 10.2147/COPD.S63485. eCollection 2014.

39.
40.

Prevalence of tracheobronchomalacia and excessive dynamic airway collapse in bronchial asthma of different severity.

Dal Negro RW, Tognella S, Guerriero M, Micheletto C.

Multidiscip Respir Med. 2013 May 14;8(1):32. doi: 10.1186/2049-6958-8-32.

41.

Novel study design to assess the utility of the copd assessment test in a primary care setting.

Gruffydd-Jones K, Marsden H, Holmes S, Kardos P, Escamilla R, Dal Negro R, Roberts J, Nadeau G, Leather D, Jones P.

BMC Med Res Methodol. 2013 May 10;13:63. doi: 10.1186/1471-2288-13-63.

42.

Pattern of airway inflammation and remodelling in mild persistent atopic asthma and in mild persistent asthma related to gastroesophageal reflux.

Dal Negro RW, Guerriero M, Micheletto C.

Eur Ann Allergy Clin Immunol. 2012 Dec;44(6):236-42.

PMID:
23441441
43.

Utility of COPD Assessment Test (CAT) in primary care consultations: a randomised controlled trial.

Gruffydd-Jones K, Marsden HC, Holmes S, Kardos P, Escamilla R, Dal Negro R, Roberts J, Nadeau G, Vasselle M, Leather DA, Jones P.

Prim Care Respir J. 2013 Mar;22(1):37-43. doi: 10.4104/pcrj.2013.00001.

44.

Essential amino acid supplementation in patients with severe COPD: a step towards home rehabilitation.

Dal Negro RW, Testa A, Aquilani R, Tognella S, Pasini E, Barbieri A, Boschi F.

Monaldi Arch Chest Dis. 2012 Jun;77(2):67-75.

45.

Coping with asthma: is the physician able to identify patient's behaviour?

Braido F, Baiardini I, Bordo A, Menoni S, Di Marco F, Centanni S, Girbino G, Dal Negro R, Brusasco V, Le LA, Canonica GW.

Respir Med. 2012 Dec;106(12):1625-30. doi: 10.1016/j.rmed.2012.09.007. Epub 2012 Oct 2.

46.

Changes in blood hemoglobin and blood gases PaO2 and PaCO2 in severe COPD overa three-year telemonitored program of long-term oxygen treatment.

Dal Negro RW, Tognella S, Bonadiman L, Turco P.

Multidiscip Respir Med. 2012 Jul 17;7(1):15. doi: 10.1186/2049-6958-7-15.

47.

A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.

Dal Negro RW, Tognella S, Pradelli L.

J Asthma. 2012 Oct;49(8):843-8. doi: 10.3109/02770903.2012.717659. Epub 2012 Sep 7.

PMID:
22954018
48.

Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe.

Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler Cataluña JJ, van der Molen T, Adamek L, Banik N.

Prim Care Respir J. 2012 Sep;21(3):329-36. doi: 10.4104/pcrj.2012.00065.

49.

Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.

Riccio AM, Dal Negro RW, Micheletto C, De Ferrari L, Folli C, Chiappori A, Canonica GW.

Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):475-84.

PMID:
22697079
50.

Use of aerosols in bronchiectasis patients.

Dal Negro RW, Micheletto C, Tognella S.

Monaldi Arch Chest Dis. 2011 Sep;75(3):185-93. Review.

Supplemental Content

Loading ...
Support Center